Join
Live feed
·
PRReleasevia Quantisnow
ImmunityBio Inc. logo

ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million

ByQuantisnow·Wall Street's wire, on your screen.
IBRX· ImmunityBio Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IBRX (ImmunityBio Inc.) and more on Quantisnow.